IP Library Granted Patent US 8,088,124
Granted Patent B2
US 8,088,124 · App. 11/625,213 · Granted Jan 3, 2012

System and method for precise beam positioning in ocular surgery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,124
App. No.
11/625,213
Granted
Jan 3, 2012
Kind
B2
Abstract

A system and method for ocular surgery includes a delivery system for generating and guiding a surgical laser beam to a focal point in a treatment area of an eye. Additionally, a contact device is employed for using the eye to establish a reference datum. Further, an optical detector is coupled to the beam path of the surgical laser to create a sequence of cross-sectional images. Each image visualizes both the reference datum and the focal point. Operationally, a computer then uses these images to position and move the focal point in the treatment area relative to the reference datum for surgery.

Claims (35)

1. An apparatus for directing a surgical laser beam to tissue in a treatment area of an eye of a patient during ocular surgery, the apparatus comprising:

a surgical laser source providing a surgical laser beam;

a beam delivery system for guiding the surgical laser beam along a beam path to a desired focal point in the treatment area;

an optical detector for creating a planar image of eye tissue wherein the planar image includes visualizations of a selected reference datum and the treatment area and wherein the reference datum is related to an anatomical feature of the eye;

a computer means, connected to the beam delivery system and to the optical detector, for using the planar image to position the focal point in the treatment area relative to the reference datum, and to guide the beam during surgery;

a means for sequentially creating a plurality of images with the optical detector;

a means for continuously monitoring the reference datum with the computer;

a means for using the reference datum to determine a delta for each image, wherein the delta is a distance between an actual position of the focal point and the position of the desired focal point; and

a means in the beam delivery system for maintaining the delta at a substantial null.

2. An apparatus as recited in claim 1 wherein the surgical laser beam comprises a sequence of femtosecond pulses.

3. An apparatus as recited in claim 1 further comprising a contact device mounted on the beam delivery system for engagement with the eye to establish the reference datum.

4. An apparatus as recited in claim 3 wherein the contact device is a contact lens and the reference datum is an interface between an external surface of the eye and the contact lens.

5. An apparatus as recited in claim 1 wherein the reference datum is selected from a group consisting of an anterior surface of a cornea, a posterior surface of a cornea, a boundary of a crystalline lens, and a fundus of an eye.

6. An apparatus as recited in claim 1 wherein the optical detector employs techniques selected from a group comprising optical coherence tomography (OCT), confocal microscopy, Scheimpflug principle and second harmonic generation microscopy.

7. An apparatus as recited in claim 6 wherein a portion of the beam path is in the plane of the image.

8. An apparatus as recited in claim 1 wherein the beam delivery system, in sequence along the beam path, comprises:

a scanning unit for moving the focal point of the surgical laser beam in orthogonal x, y and z directions; and

a focusing lens for establishing the focal point.

9. An apparatus as recited in claim 8 wherein the optical detector includes a secondary scanning unit and is positioned to couple a diagnostic beam onto the beam path of the surgical laser beam at a point between the scanning unit and the focusing lens.

10. An apparatus as recited in claim 9 wherein the wavelength of the surgical laser beam is approximately one thousand nanometers (λ s =1,000 nm).

11. An apparatus for directing a surgical laser beam to a treatment area of a substantially transparent material, wherein the transparent material includes a first portion having a first refractive index and a second portion having a second refractive index to establish an interface therebetween, the apparatus comprising:

a surgical laser source providing a surgical laser beam;

a means for guiding the surgical laser beam along a beam path to a desired focal point in the treatment area;

an optical coherence tomography (OCT) detector for creating a planar image of the material, wherein the planar image includes visualizations of a selected reference datum and the treatment area and wherein the reference datum is related to the interface;

a computer means for positioning the focal point in the treatment area relative to the reference datum in the image, and for guiding the beam during surgery;

a means for sequentially creating a plurality of images with the optical detector;

a means for continuously monitoring the reference datum with the computer;

a means for using the reference datum to determine a delta for each image, wherein the delta is a distance between an actual position of the focal point and the position of the desired focal point; and

a means for maintaining the delta at a substantial null.

12. An apparatus as recited in claim 11 wherein the surgical laser generating means comprises:

a primary scanning unit for moving the focal point of the surgical laser beam in orthogonal x, y and z directions; and

a focusing lens for establishing the focal point.

13. An apparatus as recited in claim 12 further comprising a secondary scanning unit, wherein the secondary scanning unit is positioned to couple a diagnostic beam onto the beam path of the surgical laser beam at a point between the primary scanning unit and the focusing lens.

14. An apparatus as recited in claim 11 wherein the transparent material is in an eye and the apparatus further comprises a contact lens mounted on the beam delivery system for engagement with the eye to establish the reference datum, and wherein the reference datum is an interface between an external surface of the eye and the contact lens.

15. An apparatus as recited in claim 11 wherein the planar image is a cross-sectional image.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →